Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients

Acta Psychiatrica Scandinavica

Volumn 122, Issue 5, 2010, Pages 367-374

  Baandrup, L ^a   Allerup, P ^b   Lublin, H ^a   Nordentoft, M ^a   Peacock, L ^a   Glenthoj, B ^a  

^a Mental Health Services CPH   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

intervention studies; practice guideline; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; OLANZAPINE; PALIPERIDONE; PENFLURIDOL; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROMAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT EDUCATION; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIOECONOMICS;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SCHIZOPHRENIA; YOUNG ADULT;

EID: 77957341547     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01553.x     Document Type: Article

References (46)

1. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009 35 : 458 468.
2. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 2008 31 : 7 20.
3. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009 119 : 419 425.
4. IPAP Schizophrenia Algorithm. Available at: http://www.ipap.org, 2006. Accessed 5 January 2008.
5. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999 60 : 649 657.
6. The National Institute for Clinical Excellence. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. London : The National Institute for Clinical Excellence, 2002.
7. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006 7 : 5 40. (Pubitemid 43878525)
8. Taylor D, Paton C, Kerwin R. The Maudsley prescribing guidelines, 9th edn. London : Informa Healthcare, 2007.
9. Botts S, Hines H, Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr Serv 2003 54 : 1086.
10. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002 28 : 75 84.
11. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004 65 : 1377 1388.
12. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003 17 : 223 229.
13. Forbruget af antipsykotika blandt 18-64 årige patienter med skizofreni, mani eller bipolar affektiv sindslidelse. Sundhedsstyrelsen, 2006 (Danish Report).
14. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998 317 : 465 468.
15. Farmer AP, Legare F, Turcot L et al. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2008 : CD004398.
16. Forsetlund L, Bjorndal A, Rashidian A et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2009 : CD003030.
17. Jamtvedt G, Young JM, Kristoffersen DT, O'brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2006 : CD000259.
18. O'brien MA, Rogers S, Jamtvedt G et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007 : CD000409.
19. Thomson O'Brien MA, Freemantle N, Oxman AD, Wolf F, Davis DA, Herrin J. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2001 : CD003030.
20. Wensing M, Van Der Weijden T, Grol R. Implementing guidelines and innovations in general practice: which interventions are effective? Br J Gen Pract 1998 48 : 991 997.
21. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003 362 : 1225 1230.
22. Grimshaw J, Eccles M, Thomas R et al. Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966-1998. J Gen Intern Med 2006 21 (Suppl. 2 S14 S20.
23. Analyse af psykiatriområdet - forskelle og ligheder i regionen. Region Hovedstaden. Afrapportering fra Underudvalget for Psykiatri og Social 2007 (Danish Report).
24. Grimshaw J, Campbell M, Eccles M, Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam Pract 2000 17 (Suppl. 1 S11 S16.
25. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003 12 : 41 48.
26. Kreyenbuhl JA, Valenstein M, Mccarthy JF, Ganoczy D, Blow FC. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007 58 : 489 495.
27. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 2002 26 : 411 414. (Pubitemid 35331237)
28. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007 29 : 183 195.
29. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005 187 : 243 247.
30. Drummond MF, Sculpher MJ, Torrance GW, O'brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd edn. New York : Oxford University Press, 2005.
31. Becker PM. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol 2006 8 : 367 375.
32. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry 2008 20 : 15 20.
33. Cates ME, Jackson CW, Feldman JM, Stimmel AE, Woolley TW. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009 45 : 251 254.
34. Checkland K, Harrison S, Marshall M. Is the metaphor of 'barriers to change' useful in understanding implementation? Evidence from general medical practice. J Health Serv Res Policy 2007 12 : 95 100.
35. Ballentine NH. Polypharmacy in the elderly: maximizing benefit, minimizing harm. Crit Care Nurs Q 2008 31 : 40 45.
36. Castelino RL, Bajorek BV, Chen TF. Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services. Ann Pharmacother 2009 43 : 1096 1106.
37. Milton JC, Jackson SH. Inappropriate polypharmacy: reducing the burden of multiple medication. Clin Med 2007 7 : 514 517.
38. Zermansky AG, Silcock J. Is medication review by primary-care pharmacists for older people cost effective? A narrative review of the literature, focusing on costs and benefits. Pharmacoeconomics 2009 27 : 11 24.
39. Weinmann S, Hoerger S, Erath M, Kilian R, Gaebel W, Becker T. Implementation of a schizophrenia practice guideline: clinical results. J Clin Psychiatry 2008 69 : 1299 1306.
40. Chong SA, Ravichandran N, Poon LY, Soo KL, Verma S. Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore 2006 35 : 457 460.
41. Patrick V, Schleifer SJ, Nurenberg JR, Gill KJ. Best practices: an initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006 57 : 21 23.
42. Ungvari GS, Chow LY, Chiu HF, Ng FS, Leung T. Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin Neurosci 1997 51 : 309 314.
43. Thompson A, Sullivan SA, Barley M et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial. Psychol Med 2008 38 : 705 715.
44. Chuang WC, Crismon ML. Evaluation of a schizophrenia medication algorithm in a state hospital. Am J Health Syst Pharm 2003 60 : 1459 1467.
45. Owen RR, Hudson T, Thrush C, Thapa P, Armitage T, Landes RD. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia. Med Care 2008 46 : 686 691.
46. Morton V, Torgerson DJ. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract 2005 11 : 59 65.